CDK4 and breast cancer: In order to analyze the role of RB1 heterozygous loss as biomarker of resistance to CDK4/6i in patients, we obtained genomic and clinical data of metastatic BC patients included in the Hartwig Medical Foundation (HMF) cohort36.